SIC
COCP icon

Samalin Investment Counsel’s Cocrystal Pharma COCP Stock Holding History

Samalin Investment Counsel’s Portfolio COCP Stock Details COCP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-83
Closed – – 208
2019
Q4 		$0 Buy
+83
New +$829 ﹤0.01% 545

Other funds holding COCP

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
EU
Emory University Atlanta, Georgia $267M AUM 48.26% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Samalin Investment Counsel's COCP Position: Q1 2020 in Review

Samalin Investment Counsel sold out of Cocrystal Pharma (COCP) in Q1 2020, closing a stake of 83 shares.

Samalin Investment Counsel first reported a position in COCP in Q4 2019 and held it in 1 quarter. The position peaked at $0 in Q4 2019. 24 funds tracked by Wall St. Rank hold COCP as of Q1 2020.

  • Samalin Investment Counsel reported no remaining Cocrystal Pharma position as of Q1 2020 after selling out during the quarter.
  • Samalin Investment Counsel sold 83 Cocrystal Pharma shares in Q1 2020.
  • Samalin Investment Counsel first reported a position in Cocrystal Pharma in Q4 2019 and held it in 1 quarter.
  • Samalin Investment Counsel's Cocrystal Pharma position peaked at $0 in Q4 2019.
  • 24 funds tracked by Wall St. Rank held Cocrystal Pharma as of Q1 2020.

Based on Samalin Investment Counsel's 13F filing for Q1 2020, filed 4 May 2020.